AC Immune (NASDAQ:ACIU) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of AC Immune (NASDAQ:ACIU) in a report published on Friday morning,Benzinga reports. They currently have a $16.00 price target on the stock.

Separately, StockNews.com downgraded shares of AC Immune from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st.

AC Immune Stock Performance

AC Immune stock traded down $0.36 during midday trading on Friday, reaching $3.19. 234,162 shares of the company were exchanged, compared to its average volume of 344,867. The company has a market capitalization of $315.62 million, a price-to-earnings ratio of -6.93 and a beta of 1.28. The firm’s 50-day simple moving average is $3.28 and its 200-day simple moving average is $3.48. AC Immune has a 1 year low of $2.25 and a 1 year high of $5.14.

Institutional Investors Weigh In On AC Immune

Several hedge funds have recently modified their holdings of ACIU. Renaissance Technologies LLC raised its stake in AC Immune by 26.4% during the second quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock worth $2,602,000 after purchasing an additional 136,300 shares during the period. Assenagon Asset Management S.A. boosted its holdings in AC Immune by 294.7% in the second quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock valued at $1,755,000 after acquiring an additional 328,312 shares during the last quarter. BNP Paribas Financial Markets grew its position in AC Immune by 315.6% during the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock valued at $33,000 after acquiring an additional 8,423 shares during the period. Lazard Asset Management LLC acquired a new stake in AC Immune during the first quarter worth about $30,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in AC Immune by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock worth $72,000 after acquiring an additional 7,400 shares during the last quarter. 51.36% of the stock is owned by institutional investors and hedge funds.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.